Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 





-
...TBI increases risk of dementia by as much as two-fold
  

ALSP Inc. is led by a dedicated team of experienced executives, scientists and thought leaders that have extensive business and clinical experience in drug development.






Scientific Advisors

Scientific Advisors


Vivian Hook, Ph.D.

Scientific Founder and Chief Scientific Advisor of ALSP Inc. and Professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego

 

Professor Hook has over 20 years experience in the field of neuroprotease research and is the author of over 160 scientific articles and books on that subject. Dr. Hook previously was a Professor at the Buck Institute for Aging Research, Novato, California, Professor of Medicine and Neuroscience at the University of California, San Diego and a Professor at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. She was trained as a molecular pharmacologist and did post-doctoral studies at the National Institute of Health, Bethesda, Maryland, with Dr. Julius Axelrod, a Nobel Prize winner for his research in neuroscience. She holds a Ph.D. in Pharmacology from the University of California, San Francisco and a BA in Medical Physics from the University of California Berkeley.

 

Col. (Ret) Dallas Hack, M.D. Combat Casualty Care

Col.(Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
Col.(Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
 
Col.(Ret) Dallas C. Hack, M.D. graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He entered active duty in September 1987 to accept a position in clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and completed a residency in General Preventive Medicine in 1993. He also has a MPH from Johns Hopkins University, a MSS from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.
 
Since 2008, Dr. Hack has been the director of the Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, where he coordinated leading edge research focused on new techniques and products to save the lives and reduce the morbidity of troops injured in the line of duty. In addition, he served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. Advances in Combat Casualty Care have reduced battlefield deaths from wounds to historic lows and are improving care at civilian trauma centers as well. 
 
While in the military, Dr. Hack initiated and shepherded a collaboration between the DOD and the FDA called the TBI Endpoints Development (TED) program, which was established to qualify surrogate markers for TBI. He remains involved with this collaboration. Some of these markers are now undergoing clinical trials. Dr. Hack is also currently shepherding a joint venture between the DOD and the NCAA in the area of TBI (see more about Dr. Hack here).
 
Col. Hack has been awarded the Bronze Star Medal, Meritorious Service Medal with six Oak Leaf Clusters, the Army Commendation Medal with three Oak Leaf Clusters, and the Army Achievement Medal. He is also the recipient of the Order of Military Medical Merit.
Col.(Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
U.S. Army Medical Research and Material Command

Since 2008, Col. Dallas Hack, MD was the director of the Combat Casualty Care Research Program and Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, coordinating leading edge-research focused on TBI. He also served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. He has been awarded numerous medals, including the Bronze Star and Legion of Merit.

Dr. Hack graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He was recruited into active duty in September 1987, to modernize clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) completing a residency in General Preventive Medicine in 1995. He also has a MPH from Johns Hopkins, a Master of Strategic Studies from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management. Read more about Dr. Hack here...


Stephen Jacobsen, Ph.D.

Former Senior Project Director, Neuroscience iMed, AstraZeneca Neurosciences

 

Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Project Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for two years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years.  Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid.  In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine.

 

Dr. Jacobsen obtained his BS in Chemistry and Physics and a MS in Biology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from New Jersey Medical School.


Joyce Williams, MBA, RAC

Regulatory Affairs Consultant


Ms. Williams is President and Principal Consultant at ProFocus Regulatory Solutions in La Jolla, CA. She provides regulatory and development consulting services for pharmaceutical, biotech and device companies . She has been involved in the regulatory strategy ALSP's compounds since the first compound entered development.  

Prior to establishing her consulting business, Ms. Williams held the positions of VP, Regulatory Affairs (RA) at Arena Pharmaceuticals; Executive Director of RA for Johnson and Johnson; VP Regulatory and Clinical Affairs at Telios Pharmaceuticals; VP RA at Monsanto Corp. She has been responsible for the successful submission of one approved 510K, four approved NDAs and one approved ANDA.   


Lawrence F. Marshall, M.D.

Professor Emeritus, Neurology UCSD


Dr. Marshall is an internationally renowned research expert in traumatic head injury. Throughout his research career, Dr. Marshall has been awarded neurosurgery research grants totaling in the millions. He has conducted research studies in a wide range of areas related to central nervous system trauma and severe head injury.


Kenneth Grabstein, Ph.D.

Inflammation Advisor


Kenneth Grabstein, Ph.D. was the Chief Scientific Officer of Allozyne Inc., a biotechnology company dedicated to developing technologies and therapeutics that address key unmet medical needs in cancer and inflammatory diseases. Dr. Grabstein was also the Co-Founder of Corixa Corporation. At Corixa, Dr. Grabstein built and lead a research team of 100 scientists engaged in the discovery and development of immuno-therapeutics and played a central role in moving projects from concept or in-licence to Phase I, II, III and approval. Prior to his work at Corixa, Dr. Grabstein spent 12 years at Immunex, where he was a Director of Immunology and was engaged in research involving the discovery and characterization of cytokines and other protein immuno-modulators, and their receptors. This work led to the development and approval of GM-CSF (Leukine) and TNF Receptor (Enbrel) which have become successful commercial products. Dr. Grabstein received his Ph.D. in Immunology from U.C. Berkeley followed by a postdoctoral fellowship at Immunex Corporation in 1982, where he was one of the first 30 employees. Dr. Grabstein has an Affiliate Faculty position at both the University of Washington and the Fred Hutchinson Cancer Research Center and has served on the University of Washington Medical School Industry Advisory Committee.


Michael Grundman, M.D. M.Ph, Acting CMO

Acting Chief Medical Officer, ALSP, Inc

 

Michael Grundman, M.D. M.Ph, is President and CEO of Global R&D Partners, LLC, a pharmaceutical consulting firm based in San Diego, California. The mission of Global R&D Partners, LLC is to help pharmaceutical and biotechnology companies develop novel agents for the diagnosis and treatment of serious and life threatening diseases.

 

Dr. Grundman previously served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy, LLC and as Vice President of Clinical Development at Elan Pharmaceuticals, Inc. Prior to joining industry Dr. Grundman was Associate Director of the Alzheimer's Disease Cooperative Study (ADCS) at the University of California, San Diego (UCSD) and is currently an Adjunct Professor of Neurosciences at UCSD. Dr. Grundman received his BA from New York University magna cum laude with Honors in Biochemistry. He obtained his MD and Neurology training at the Albert Einstein College of Medicine and a Master of Public Health degree from Columbia University. Dr. Grundman previously served on the FDA Peripheral and Central Nervous System Advisory Committee and is an inventor on a number of patents related to Alzheimer's disease therapy. Dr. Grundman has lectured at numerous national and international scientific meetings and has published over 60 articles related to Alzheimer's disease and dementia.  



Col.(Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
 
Col.(Ret) Dallas C. Hack, M.D. graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He entered active duty in September 1987 to accept a position in clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and completed a residency in General Preventive Medicine in 1993. He also has a MPH from Johns Hopkins University, a MSS from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.
 
Since 2008, Dr. Hack has been the director of the Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, where he coordinated leading edge research focused on new techniques and products to save the lives and reduce the morbidity of troops injured in the line of duty. In addition, he served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. Advances in Combat Casualty Care have reduced battlefield deaths from wounds to historic lows and are improving care at civilian trauma centers as well. 
 
While in the military, Dr. Hack initiated and shepherded a collaboration between the DOD and the FDA called the TBI Endpoints Development (TED) program, which was established to qualify surrogate markers for TBI. He remains involved with this collaboration. Some of these markers are now undergoing clinical trials. Dr. Hack is also currently shepherding a joint venture between the DOD and the NCAA in the area of TBI (see more about Dr. Hack here).
 
Col. Hack has been awarded the Bronze Star Medal, Meritorious Service Medal with six Oak Leaf Clusters, the Army Commendation Medal with three Oak Leaf Clusters, and the Army Achievement Medal. He is also the recipient of the Order of Military Medical Merit.

Col.(Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
 
Col.(Ret) Dallas C. Hack, M.D. graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He entered active duty in September 1987 to accept a position in clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and completed a residency in General Preventive Medicine in 1993. He also has a MPH from Johns Hopkins University, a MSS from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.
 
Since 2008, Dr. Hack has been the director of the Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, where he coordinated leading edge research focused on new techniques and products to save the lives and reduce the morbidity of troops injured in the line of duty. In addition, he served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. Advances in Combat Casualty Care have reduced battlefield deaths from wounds to historic lows and are improving care at civilian trauma centers as well. 
 
While in the military, Dr. Hack initiated and shepherded a collaboration between the DOD and the FDA called the TBI Endpoints Development (TED) program, which was established to qualify surrogate markers for TBI. He remains involved with this collaboration. Some of these markers are now undergoing clinical trials. Dr. Hack is also currently shepherding a joint venture between the DOD and the NCAA in the area of TBI (see more about Dr. Hack here).

Col.(Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
 
Col.(Ret) Dallas C. Hack, M.D. graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He entered active duty in September 1987 to accept a position in clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and completed a residency in General Preventive Medicine in 1993. He also has a MPH from Johns Hopkins University, a MSS from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.
 
Since 2008, Dr. Hack has been the director of the Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, where he coordinated leading edge research focused on new techniques and products to save the lives and reduce the morbidity of troops injured in the line of duty. In addition, he served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. Advances in Combat Casualty Care have reduced battlefield deaths from wounds to historic lows and are improving care at civilian trauma centers as well. 
 
While in the military, Dr. Hack initiated and shepherded a collaboration between the DOD and the FDA called the TBI Endpoints Development (TED) program, which was established to qualify surrogate markers for TBI. He remains involved with this collaboration. Some of these markers are now undergoing clinical trials. Dr. Hack is also currently shepherding a joint venture between the DOD and the NCAA in the area of TBI (see more about Dr. Hack here).
 
Col. Hack has been awarded the Bronze Star Medal, Meritorious Service Medal with six Oak Leaf Clusters, the Army Commendation Medal with three Oak Leaf Clusters, and the Army Achievement Medal. He is also the recipient of the Order of Military Medical Merit..

Col.(Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
 
Col.(Ret) Dallas C. Hack, M.D. graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He entered active duty in September 1987 to accept a position in clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and completed a residency in General Preventive Medicine in 1993. He also has a MPH from Johns Hopkins University, a MSS from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.
 
Since 2008, Dr. Hack has been the director of the Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, where he coordinated leading edge research focused on new techniques and products to save the lives and reduce the morbidity of troops injured in the line of duty. In addition, he served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. Advances in Combat Casualty Care have reduced battlefield deaths from wounds to historic lows and are improving care at civilian trauma centers as well. 
 
While in the military, Dr. Hack initiated and shepherded a collaboration between the DOD and the FDA called the TBI Endpoints Development (TED) program, which was established to qualify surrogate markers for TBI. He remains involved with this collaboration. Some of these markers are now undergoing clinical trials. Dr. Hack is also currently shepherding a joint venture between the DOD and the NCAA in the area of TBI (see more about Dr. Hack here).
 
Col. Hack has been awarded the Bronze Star Medal, Meritorious Service Medal with six Oak Leaf Clusters, the Army Commendation Medal with three Oak Leaf Clusters, and the Army Achievement Medal. He is also the recipient of the Order of Military Medical Merit.